Forvis Mazars Wealth Advisors’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.78M Buy
17,171
+3,121
+22% +$279K 0.03% 168
2026
Q1
$1.01M Sell
14,050
-728
-5% -$56.1K 0.02% 209
2025
Q4
$1.17M Sell
14,778
-1,649
-10% -$130K 0.02% 193
2025
Q3
$1.24M Sell
16,427
-1,667
-9% -$114K 0.02% 189
2025
Q2
$1.25M Buy
18,094
+104
+0.6% +$6.82K 0.03% 189
2025
Q1
$1.22M Sell
17,990
-3,946
-18% -$236K 0.03% 191
2024
Q4
$985K Sell
21,936
-4,562
-17% -$256K 0.02% 224
2024
Q3
$1.67M Sell
26,498
-852
-3% -$49.7K 0.04% 181
2024
Q2
$1.62M Sell
27,350
-1,504
-5% -$94.1K 0.04% 174
2024
Q1
$2.3M Buy
28,854
+2,037
+8% +$156K 0.06% 150
2023
Q4
$2.12M Buy
26,817
+475
+2% +$33.8K 0.06% 151
2023
Q3
$1.84M Sell
26,342
-12,437
-32% -$881K 0.06% 154
2023
Q2
$2.68M Buy
38,779
+15,062
+64% +$1.07M 0.08% 144
2023
Q1
$1.76M Buy
23,717
+990
+4% +$83K 0.06% 158
2022
Q4
$2.12M Buy
22,727
+771
+4% +$74.4K 0.07% 140
2022
Q3
$2.09M Buy
21,956
+1,284
+6% +$127K 0.08% 135
2022
Q2
$1.92M Sell
20,672
-448
-2% -$43.7K 0.08% 131
2022
Q1
$2.14M Buy
21,120
+1,768
+9% +$186K 0.09% 104
2021
Q4
$2M Buy
19,352
+730
+4% +$67.5K 0.08% 102
2021
Q3
$1.58M Buy
18,622
+26
+0.1% +$2.18K 0.07% 113
2021
Q2
$1.55M Sell
18,596
-527
-3% -$43.2K 0.07% 114
2021
Q1
$1.44M Sell
19,123
-2,559
-12% -$186K 0.07% 113
2020
Q4
$1.48M Buy
21,682
+3,932
+22% +$256K 0.07% 122
2020
Q3
$1.04M Buy
17,750
+1,315
+8% +$81.8K 0.06% 132
2020
Q2
$1.07M Buy
16,435
+3,542
+27% +$223K 0.07% 126
2020
Q1
$765K Buy
12,893
+3,148
+32% +$210K 0.06% 131
2019
Q4
$724K Buy
9,745
+2,753
+39% +$193K 0.05% 147
2019
Q3
$441K Sell
6,992
-3,763
-35% -$223K 0.04% 188
2019
Q2
$586K Sell
10,755
-2,597
-19% -$140K 0.05% 148
2019
Q1
$720K Buy
13,352
+6,210
+87% +$383K 0.06% 127
2018
Q4
$468K Buy
7,142
+705
+11% +$52.6K 0.05% 140
2018
Q3
$507K Buy
6,437
+25
+0.4% +$1.79K 0.04% 144
2018
Q2
$413K Buy
6,412
+482
+8% +$31.8K 0.04% 163
2018
Q1
$369K Sell
5,930
-96
-2% -$6.89K 0.04% 181
2017
Q4
$437K Sell
6,026
-993
-14% -$72.2K 0.04% 163
2017
Q3
$571K Buy
7,019
+722
+11% +$57.1K 0.06% 124
2017
Q2
$507K Buy
6,297
+364
+6% +$28.7K 0.06% 137
2017
Q1
$466K Buy
5,933
+158
+3% +$12.6K 0.06% 129
2016
Q4
$456K Sell
5,775
-218
-4% -$17.6K 0.06% 128
2016
Q3
$533K Sell
5,993
-1,992
-25% -$188K 0.07% 110
2016
Q2
$764K Sell
7,985
-169
-2% -$16.8K 0.11% 86
2016
Q1
$846K Sell
8,154
-426
-5% -$41.4K 0.14% 81
2015
Q4
$839K Buy
8,580
+1,167
+16% +$114K 0.13% 80
2015
Q3
$715K Buy
7,413
+2,281
+44% +$240K 0.13% 82
2015
Q2
$538K Sell
5,132
-199
-4% -$20.3K 0.08% 98
2015
Q1
$550K Buy
5,331
+519
+11% +$52.5K 0.08% 102
2014
Q4
$463K Buy
4,812
+981
+26% +$86.4K 0.08% 101
2014
Q3
$305K Hold
3,831
0.05% 109
2014
Q2
$289K Sell
3,831
-275
-7% -$20.8K 0.05% 115
2014
Q1
$309K Buy
4,106
+8
+0.2% +$565 0.05% 125
2013
Q4
$293K Sell
4,098
-54
-1% -$3.47K 0.05% 128
2013
Q3
$236K Sell
4,152
-90
-2% -$5.36K 0.05% 129
2013
Q2
$243K Buy
+4,242
New +$246K 0.19% 88

Other funds holding CVS

Forvis Mazars Wealth Advisors's CVS Position: Q2 2026 in Review

Forvis Mazars Wealth Advisors increased its CVS Health (CVS) stake by 22% in Q2 2026, buying an estimated $279K and bringing the position to 17,171 shares worth $1.78M. The position accounts for 0.03% of the portfolio, ranked #168.

Forvis Mazars Wealth Advisors first reported a position in CVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.68M in Q2 2023. 2,061 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • Forvis Mazars Wealth Advisors held 17,171 shares of CVS Health worth $1.78M as of Q2 2026.
  • Forvis Mazars Wealth Advisors bought 3,121 CVS Health shares in Q2 2026, an estimated $279K.
  • CVS Health made up 0.03% of Forvis Mazars Wealth Advisors's portfolio in Q2 2026, its #168 holding.
  • Forvis Mazars Wealth Advisors first reported a position in CVS Health in Q2 2013 and has held it in 53 quarters since.
  • Forvis Mazars Wealth Advisors's CVS Health position peaked at $2.68M in Q2 2023.
  • 2,061 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on Forvis Mazars Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.